Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.65 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.54 |
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | TERT | O14746 | 4/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MMP14 | P50281 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6370986 | 0.90 | MAOA (0.77) | MAOAHSP90AA1HSP90AB1TERTCASP3 | |
| SCHEMBL13564105 | 0.85 | MAOA (0.71) | MAOAHSP90AA1HSP90AB1TERTCASP3 | |
| SCHEMBL11880339 | 0.83 | MAOA (0.67) | MAOAHSP90AA1HSP90AB1TERTCASP3 | |
| SCHEMBL7034212 | 0.82 | MEN1 (0.70) | HSP90AA1HSP90AB1ADORA2ACASP3ALDH1A1 | |
| SCHEMBL30546483 | 0.82 | MEN1 (0.70) | HSP90AA1HSP90AB1ADORA2ACASP3ALDH1A1 | |
| SCHEMBL9846483 | 0.81 | MAOA (0.74) | MAOAHSP90AA1HSP90AB1TERTCASP3 | |
| SCHEMBL8604260 | 0.81 | MAOA (0.65) | MAOAHSP90AA1HSP90AB1TERTCASP3 | |
| SCHEMBL7193552 | 0.81 | MAOA (0.74) | MAOAHSP90AA1HSP90AB1TERTCASP3 | |
| SCHEMBL8777722 | 0.81 | MEN1 (0.69) | MAOAHSP90AA1HSP90AB1ADORA2ATERT | |
| SCHEMBL11568163 | 0.80 | MAOA (0.63) | MAOAHSP90AA1HSP90AB1TERTCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335676-B2 | Methods for treating inflammatory conditions or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-02-26 | — | — | US | disclosed |
| US-7119114-B1 | Pyrazoloanthrone and derivatives thereof as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1608363-A1 | METHODS FOR TREATING INFLAMMATORY CONDITIONS OR INHIBITING JNK | Signal Pharmaceuticals, Inc. (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004084891-A1 | METHODS FOR TREATING INFLAMMATORY CONDITIONS OR INHIBITING JNK | SIGNAL PHARMACEUTICALS, LLC (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040176434-A1 | Methods for treating inflammatory conditions or inhibiting JNK | BENNETT BRYDON L (US) | 2004-09-09 | — | — | US | disclosed |
| US-20040072888-A1 | Methods for treating inflammatory conditions or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-04-15 | — | — | US | disclosed |
| EP-1218347-A1 | PYRAZOLOANTHRONE AND DERIVATIVES THEREOF AS JNK INHIBITORS AND THEIR COMPOSITIONS | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001012609-A1 | PYRAZOLOANTHRONE AND DERIVATIVES THEREOF AS JNK INHIBITORS AND THEIR COMPOSITIONS | SIGNAL PHARMACEUTICALS, INC. (US) | 2001-02-22 | — | — | WO | disclosed |
| US-4082778-A | ANTHRAQUINONE DYES, ORGANIC PIGMENTS | CIBA-GEIGY CORPORATION (US) | 1978-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072888-A1 | Methods for treating inflammatory conditions or inhibiting JNK | MAPKAPK2, MAPK1, MAP3K1 | MAOA 3672/4885HSP90AA1 336/4885HSP90AB1 248/4885 |
| US-20040176434-A1 | Methods for treating inflammatory conditions or inhibiting JNK | MAPKAPK2, MAPK1, MAP3K1 | MAOA 3672/4885HSP90AA1 336/4885HSP90AB1 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.